v3 Template
I

Immunic, Inc.

Biotechnology New York, USA ~520 employees
Founded
--
Employees (Est.)
~520
26 leaders known
Total Funding
$980.2M
Funding Rounds
7
Last Funding
2026-02-17

About Immunic, Inc.

Immunic Therapeutics is a biotechnology company focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, with a mission to provide high-quality, oral treatment options with comprehensive therapeutic efficacy and outstanding safety for patients, particularly those with multiple sclerosis and celiac disease.

Products & Services

Vidofludimus Calcium:An oral therapy aimed at elevating the standard of care for multiple sclerosis patients with comprehensive therapeutic efficacy and outstanding safety and tolerability.
IMU-856:An oral treatment option for celiac disease patients, designed to be efficacious, safe, and well-tolerated to improve their quality of life by eliminating debilitating symptoms.
IMU-381:An oral small molecule therapy under development for chronic inflammatory and autoimmune diseases, with specific details not provided in the content.

Specialties

Oral small molecule therapies Chronic inflammatory diseases Autoimmune diseases Multiple sclerosis treatment Celiac disease treatment

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Private Placement
T: -
FT: Private Placement 		A: 200000000
MR: -
FA: USD 200 Million
FAN: 200000000 		D: 2026-02-17
FD: 2026-02-17 		13 investors
2 RT: Private Placement
T: -
FT: Private Placement 		A: 400000000
MR: -
FA: up to USD 400 million
FAN: 400000000 		D: 2026-02-13
FD: 2026-02-13 		13 investors
3 RT: Public Offering
T: -
FT: Public Offering 		A: 65000000
MR: -
FA: approximately $65 million
FAN: 65000000 		D: 2025-06-03
FD: 2025-06-03 		5 investors
4 RT: Underwritten Public Offering
T: -
FT: Underwritten Public Offering 		A: 65000000
MR: -
FA: $65 million
FAN: 65000000 		D: 2025-05-29
FD: 2025-05-29 		4 investors
5 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering 		A: 5100000
MR: -
FA: 5.1 million
FAN: 5100000 		D: 2025-04-10
FD: 2025-04-10 		1 investors
6 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering 		A: 5100000
MR: -
FA: approximately $5.1 million
FAN: 5100000 		D: 2025-04-09
FD: 2025-04-09 		1 investors
7 RT: Private Placement
T: -
FT: Private Placement 		A: 240000000
MR: -
FA: up to $240 million
FAN: 240000000 		D: 2024-01-05
FD: 2024-01-05 		6 investors
Private Placement Latest
2026-02-17
$200.0M
13 investors (Pro only)
Private Placement 2026-02-13
$400.0M
Public Offering 2025-06-03
$65.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

D

Dr. Daniel Vitt

Chief Executive Officer and Director

LinkedIn (Pro only)
J

Jason Tardio

President and Chief Operating Officer

LinkedIn (Pro only)
D

Dr. Andreas Muehler

Chief Medical Officer

LinkedIn (Pro only)
D

Dr. Hella Kohlhof

Chief Scientific Officer

G

Glenn Whaley

Chief Financial Officer

P

Patrick Walsh

Chief Business Officer

View 23 more team members with Pro

Unlock Full Team Directory

Recent News

Immunic, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
imux.com
Industries
Biotechnology
Company Size
~520 employees (est.)
Locations
New York, USA
NEW YORK, USA
New York

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro